Dasatinib and Afinitor drug interactions - from FDA reports


Drug interactions are reported only by a few people who take Dasatinib and Afinitor together. This review analyzes the effectiveness and drug interactions between Dasatinib and Afinitor. It is created by eHealthMe based on reports of 5 people who take the same drugs from FDA, and is updated regularly.

How to use this study: bring a copy to your health teams to ensure drug risks and benefits are fully discussed and understood.


Peer to Peer mobile support

Peer support for this study is available on our Ginger Health app. It's free, anonymous and secure. The app is ideal for people taking multiple medications or having multiple conditions.



On Feb, 19, 2019

5 people who take Dasatinib, Afinitor are studied.


Number of reports submitted per year:

Dasatinib and Afinitor drug interactions.

Most common drug interactions over time *:

< 1 month:
  1. Neoplasm malignant (cancer tumour)
  2. Neoplasm progression (growth of tumour)
  3. Po2 decreased
  4. Ascites (accumulation of fluid in the abdominal cavity)
  5. Asthenia (weakness)
  6. Atelectasis (partial or complete collapse of the lung)
  7. Autoimmune disorder (a condition in which the immune system attacks the body's normal substances and tissue)
  8. Blood creatinine increased
  9. Blood glucose decreased
  10. Dehydration (dryness resulting from the removal of water)
1 - 6 months:
  1. C-reactive protein increased
  2. Cerebral haemorrhage (bleeding within the brain)
  3. Death
  4. Neoplasm malignant (cancer tumour)
  5. Neoplasm progression (growth of tumour)
  6. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  7. Po2 decreased
  8. Rash
6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

n/a

5 - 10 years:

n/a

10+ years:

n/a

not specified:
  1. Death
  2. Malignant neoplasm progression (cancer tumour came back)
  3. Aphasia (damage to the parts of the brain that control language)
  4. Brain neoplasm (tumour of brain)
  5. Hemianopia homonymous (visual field defect involving either the two right or the two left halves of the visual fields of both eyes)
  6. Neoplasm recurrence (reoccurrence of tumour)
  7. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  8. Paresis (condition of muscular weakness)
  9. Rash
  10. Ascites (accumulation of fluid in the abdominal cavity)

Most common drug interactions by gender *:

female:
  1. Ascites (accumulation of fluid in the abdominal cavity)
  2. Asthenia (weakness)
  3. Atelectasis (partial or complete collapse of the lung)
  4. Autoimmune disorder (a condition in which the immune system attacks the body's normal substances and tissue)
  5. Blood creatinine increased
  6. Blood glucose decreased
  7. Dehydration (dryness resulting from the removal of water)
  8. Diarrhoea
  9. Dysgeusia (disorder of the sense of taste)
  10. Dysphagia (condition in which swallowing is difficult or painful)
male:
  1. C-reactive protein increased
  2. Cerebral haemorrhage (bleeding within the brain)
  3. Hemianopia homonymous (visual field defect involving either the two right or the two left halves of the visual fields of both eyes)
  4. Malignant neoplasm progression (cancer tumour came back)
  5. Neoplasm recurrence (reoccurrence of tumour)
  6. Paresis (condition of muscular weakness)
  7. Death
  8. Neoplasm malignant (cancer tumour)
  9. Neoplasm progression (growth of tumour)
  10. Po2 decreased

Most common drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:
  1. Death
  2. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  3. Rash
40-49:
  1. Aphasia (damage to the parts of the brain that control language)
  2. Brain neoplasm (tumour of brain)
  3. Hemianopia homonymous (visual field defect involving either the two right or the two left halves of the visual fields of both eyes)
  4. Malignant neoplasm progression (cancer tumour came back)
  5. Neoplasm recurrence (reoccurrence of tumour)
  6. Paresis (condition of muscular weakness)
50-59:
  1. Blood glucose decreased
  2. Dehydration (dryness resulting from the removal of water)
  3. Diarrhoea
  4. Dysgeusia (disorder of the sense of taste)
  5. Dysphagia (condition in which swallowing is difficult or painful)
  6. Failure to thrive (inadequate weight gain and physical growth in children)
  7. Gout (uric acid crystals building up in the body)
  8. Grand mal convulsion (a type of generalized seizure that affects the entire brain)
  9. Hyperglycaemia (high blood sugar)
  10. Hypokalaemia (low potassium)
60+:
  1. C-reactive protein increased
  2. Cerebral haemorrhage (bleeding within the brain)
  3. Neoplasm malignant (cancer tumour)
  4. Neoplasm progression (growth of tumour)
  5. Po2 decreased

* Approximation only. Some reports may have incomplete information.

Do you take Dasatinib and Afinitor?


You are not alone:




Related studies

Dasatinib

Dasatinib has active ingredients of dasatinib. (latest outcomes from Dasatinib 4,239 users)

Afinitor

Afinitor has active ingredients of everolimus. It is often used in breast cancer metastatic. (latest outcomes from Afinitor 27,509 users)


Browse by gender and age

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+


Interactions between Dasatinib and drugs from A to Z
a b c d e f g h i j k l m n o p q r s t u v w x y z
Interactions between Afinitor and drugs from A to Z
a b c d e f g h i j k l m n o p q r s t u v w x y z
Browse all drug interactions of Dasatinib and Afinitor
a b c d e f g h i j k l m n o p q r s t u v w x y z

What would happen?

Predict new side effects and undetected conditions when you take Dasatinib and Afinitor

FDA reports used in this study



Recent updates

Recent general studies
Recent personal studies

NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Submit your testimonial

  • Please fill in your Testimonial.
  • Please enter a minimum of 10 characters for your Testimonial.
  • Please fill in your Name.

Please wait...

{progressItem}

Thank you!